0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India
The US administration announced a phased tariff schedule for generic pharmaceutical imports: zero tariff from August 1, 2026 for two years, rising to 100% for one year from around August 2028, and then to 200% from 2029 onward.
The stated objective is to push drugmakers to "reshore" generic drug manufacturing into the United States by building domestic plant and equipment before the duty-free window closes.
This generics schedule follows an earlier action in April 2026 that imposed a 100% tariff on patented (branded) pharmaceuticals and associated active pharmaceutical ingredients (APIs), from which generics and biosimilars were exempted at the time.
India is the country most exposed to this schedule: its pharmaceutical exports to the US were about $8.5-9.7 billion in FY2025-26/FY2024-25, roughly a third of India's total pharma exports of about $25-30 billion, and Indian manufacturers supply an estimated 40% of generic medicines used in the US.
Major Indian pharmaceutical companies — including Sun Pharmaceuticals, Aurobindo Pharma, Cipla, Dr. Reddy's, Biocon, Lupin, Zydus Lifesciences, Glenmark, Granules India, Jubilant, and Piramal Pharma — have collectively pledged around $19.1 billion in US investment plans, which analysts note could partly cushion the impact once higher tariffs apply.
Section 232 of the US Trade Expansion Act, 1962 — National Security Tariffs
Section 232 empowers the US President to restrict or tax imports once the Department of Commerce determines that a category of imports threatens to impair national security. Unlike ordinary trade-remedy tariffs, it does not require a finding of dumping or subsidisation by the exporting country — only a national-security risk assessment.
Key Details
- A Section 232 investigation into pharmaceuticals and APIs was initiated by the US Commerce Department in April 2025, citing America's heavy reliance on foreign-made drugs and drug ingredients as a security vulnerability.
- The April 2026 executive order imposing a 100% tariff on patented drugs and APIs cited findings that a majority of patented drugs and a very high share of associated APIs sold in the US were foreign-produced.
- Section 232 was previously used by the same administration for steel and aluminium tariffs in 2018; a 2022 WTO dispute panel found those tariffs inconsistent with WTO obligations and not validly covered by the security exception.
- The new generic-drug schedule extends this same Section 232 legal basis to the generics segment, where India — not China or the EU — holds the largest single-country share of US supply.
The tiered 0%–100%–200% tariff structure on generics is a continuation of the Section 232 pharmaceutical action rather than a separate legal instrument, meaning any Indian or WTO challenge would have to contest the same "national security" designation already used for the April 2026 branded-drug order.
Generic vs. Patented (Branded) Drugs — The Regulatory Distinction
A generic drug is a medicine that is bioequivalent to an already-approved "innovator" or branded drug — same active ingredient, dosage form, strength, and clinical effect — and is legally marketable only after the original drug's patent protection and any regulatory exclusivity period expire. This distinguishes it from patented drugs, which enjoy exclusive marketing rights and typically command much higher prices.
Key Details
- In the US, generics are approved through an Abbreviated New Drug Application (ANDA) under Section 505(j) of the Federal Food, Drug, and Cosmetic Act, which requires bioequivalence data rather than full clinical trials, making generics far cheaper to develop and produce than the original innovator drug.
- Generics accounted for over 90% of prescriptions dispensed in the US by volume, even though they represent a much smaller share of total US drug spending by value, reflecting their low unit cost.
- India is the world's largest supplier of generic medicines by volume and is often described as the "pharmacy of the world," while its exports of patented/high-value drugs to the US remain comparatively small.
Because the April 2026 tariff order targeted patented drugs and exempted generics, and India's exports are overwhelmingly generic, the new schedule specifically announced for generics is what determines India's real tariff exposure — the branded-drug order alone had limited direct impact on Indian exporters.
India's Domestic Response — PLI for Bulk Drugs and APIs
India runs a separate, pre-existing Production Linked Incentive (PLI) scheme aimed at reducing import dependence for the raw materials used to make generic drugs, distinct from the trade-policy question of US tariffs but directly relevant to India's ability to absorb tariff shocks.
Key Details
- The PLI Scheme for Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) was launched in March 2020 with an outlay of ₹6,940 crore for FY2020-21 to FY2029-30, covering 41 identified bulk drugs where India had high import dependence (historically on China).
- A complementary Bulk Drug Parks scheme (2020) supports three mega bulk-drug parks, in Himachal Pradesh, Gujarat, and Andhra Pradesh, each with an outlay of ₹1,000 crore, to build shared manufacturing infrastructure.
- These schemes target India's upstream API/KSM dependence, not the downstream US market-access risk, but strengthening domestic API manufacturing is one lever available to Indian policy to reduce cost pressure as global tariff regimes shift.
While the US tariff schedule is an external trade-policy shock, India's own PLI-for-APIs framework represents the domestic supply-side response track — reducing reliance on imported raw materials even as exporters navigate reduced access or higher costs in the US finished-generics market.
India-US Trade Relationship and Tariff Diplomacy
Tariff actions on pharmaceuticals sit within the broader arc of India-US trade negotiations, where an interim trade agreement concluded in February 2026 addressed several tariff lines, and separate US statutory tools (distinct from Section 232) have also been invoked in past disputes.
Key Details
- Section 301 of the US Trade Act, 1974 authorizes tariffs in response to "unfair trade practices" by a foreign country and is a different legal basis from the national-security rationale under Section 232; the two are not interchangeable and have different procedural requirements.
- India has previously pursued WTO dispute mechanisms against earlier US Section 232 tariffs (on steel and aluminium), underscoring the recurring friction between US unilateral tariff tools and WTO Most Favoured Nation (MFN) obligations under GATT Article I.
- The pharmaceutical tariff schedule was announced even as broader India-US trade discussions continued, indicating that sector-specific tariff actions can proceed independently of, and sometimes in parallel with, comprehensive trade-deal negotiations.
The generic-drug tariff timeline gives Indian exporters and negotiators a fixed multi-year runway (2026-2029) during which trade diplomacy, WTO recourse, or bilateral negotiation could still alter the eventual tariff outcome before the steepest 200% rate takes effect.
- Generic drug tariff schedule: 0% from August 1, 2026 (two years) → 100% for one year (around 2028) → 200% from 2029 onward
- April 2026 order: 100% tariff on patented drugs and APIs; generics and biosimilars were exempted at that time
- India's pharma exports to the US: approximately $8.5-9.7 billion (FY2024-25/FY2025-26)
- US share of India's total pharma exports: roughly one-third (India's total pharma exports are about $25-30 billion)
- Indian share of US generic drug supply: approximately 40% (US FDA data)
- Pledged US investment by Indian pharma companies: about $19.1 billion (as of May 2026 announcements)
- India's PLI scheme for APIs/KSMs/DIs: launched March 2020, outlay ₹6,940 crore, covering 41 bulk drugs, running FY2020-21 to FY2029-30
- Bulk Drug Parks scheme: three parks (Himachal Pradesh, Gujarat, Andhra Pradesh), ₹1,000 crore outlay each